Search results for "adrenal cortex hormones"

showing 10 items of 145 documents

Blood eosinophils and treatment response in hospitalized exacerbations of chronic obstructive pulmonary disease: A case-control study

2015

Background: In outpatients with chronic obstructive pulmonary disease (COPD), blood eosinophilia is considered as a biomarker of response to systemic corticosteroid therapy. However, little is known on whether blood eosinophilia is also predictive of positive clinical outcome in severe acute exacerbations of COPD requiring hospitalization. We hypothesized that blood eosinophil-positive severe acute exacerbations of COPD differ from eosinophil-negative ones in terms of response to therapy and clinical outcomes. Methods: To test our experimental hypothesis, we retrospectively analyzed medical records of patients with COPD admitted to our ward because of severe exacerbation, over a two-year pe…

MalePulmonary and Respiratory Medicinemedicine.medical_specialtyEosinophilSettore MED/10 - Malattie Dell'Apparato RespiratorioSeverity of Illness IndexdosageGlucocorticoids/administration &ampPulmonary Disease Chronic Obstructive03 medical and health sciences0302 clinical medicineAdrenal Cortex HormonesInternal medicineEosinophiliaSeverity of illnessmedicineHumansBiological markers/bloodCOPDEosinophiliaPharmacology (medical)030212 general & internal medicineIntensive care medicineAgedRetrospective StudiesAged 80 and overCOPDbusiness.industryMedical recordBiochemistry (medical)Case-control studyRetrospective cohort studyMiddle Agedmedicine.diseaserespiratory tract diseasesEosinophilsHospitalizationTreatment Outcome030228 respiratory systemCase-Control StudiesInclusion and exclusion criteriaLength of stayBiomarker (medicine)Femalemedicine.symptombusinessPulmonary Pharmacology & Therapeutics
researchProduct

GOLD 2017 treatment pathways in ‘real life’: An analysis of the DACCORD observational study

2017

Abstract Introduction The 2017 update to the Global Initiative for Obstructive Lung Disease (GOLD) strategy document includes recommendations for treatment intensification or step-down in chronic obstructive pulmonary disease (COPD), although recognises that limited supporting information is available. DACCORD is an ongoing observational, non-interventional study, recruiting patients following COPD maintenance treatment change or initiation, a subset of whom were receiving a long-acting β2-agonist (LABA) plus a long-acting muscarinic antagonist (LAMA) fixed-dose combination (FDC) on entry. Since there were no requirements in terms of prior medication (and no washout before commencing LABA/L…

MalePulmonary and Respiratory Medicinemedicine.medical_specialtyExacerbationmedicine.drug_classMuscarinic AntagonistsQuinolonesMaintenance ChemotherapyPulmonary Disease Chronic Obstructive03 medical and health sciences0302 clinical medicinePharmacotherapyAdrenal Cortex HormonesGermanyInternal medicineAdministration InhalationmedicineHumansddc:610Longitudinal StudiesProspective Studies030212 general & internal medicineAdrenergic beta-2 Receptor AgonistsAgedCOPDbiologybusiness.industryDisease ManagementMiddle AgedLamabiology.organism_classificationmedicine.diseaseGlycopyrrolateObstructive lung diseaseDrug Combinations030228 respiratory systemIndansPractice Guidelines as TopicCritical PathwaysDisease ProgressionPhysical therapyIndacaterolCorticosteroidDrug Therapy CombinationFemaleObservational studybusinesshormones hormone substitutes and hormone antagonistsmedicine.drugRespiratory Medicine
researchProduct

Assessing biomarkers in a real-world severe asthma study (ARIETTA)

2016

AbstractThe prognostic value of asthma biomarkers in routine clinical practice is not fully understood. ARIETTA (NCT02537691) is an ongoing, prospective, longitudinal, international, multicentre real-world study designed to assess the relationship between asthma biomarkers and disease-related health outcomes. The trial aims to enrol and follow for 52 weeks approximately 1200 severe asthma patients from approximately 160 sites in more than 20 countries. Severe asthmatics, treated with daily inhaled corticosteroid (≥500 μg of fluticasone propionate or equivalent) and at least 1 second controller medication are to be included. In this real-world study, patients will be treated according to the…

MaleSevere asthmaCardiac & Cardiovascular SystemsExacerbationAIRWAY INFLAMMATIONRespiratory SystemEosinophilSeverity of Illness Indexlaw.inventionDOUBLE-BLIND0302 clinical medicineQuality of lifeRandomized controlled trialAdrenal Cortex HormoneslawForced Expiratory VolumeProspective Studies030212 general & internal medicineProspective cohort studyFluticasoneEPITHELIAL-CELLSExacerbationRANDOMIZED CONTROLLED-TRIALPrognosis3. Good healthTO-SEVERE ASTHMAFemaleLife Sciences & Biomedicinemedicine.drugAdultPulmonary and Respiratory Medicinemedicine.medical_specialtyPHENOTYPESNitric Oxide1102 Cardiovascular Medicine And HaematologyFluticasone propionate03 medical and health sciencesPredictive Value of TestsAdministration InhalationSeverity of illnessmedicineHumansNITRIC-OXIDE SYNTHASEIntensive care medicineCOMBINATIONAsthmaScience & Technologybusiness.industryPULMONARY-FUNCTION1103 Clinical SciencesBiomarkerImmunoglobulin Emedicine.diseaseAsthmarespiratory tract diseasesEosinophilsBiomarker; Eosinophil; Exacerbation; Periostin; Severe asthma; Pulmonary and Respiratory MedicinePeriostin030228 respiratory systemQuality of LifeCardiovascular System & CardiologyFluticasonebusinessCell Adhesion MoleculesBiomarkersRespiratory Medicine
researchProduct

Factors reducing omalizumab response in severe asthma

2018

Background: Despite adding Omalizumab to conventional therapy, several severe asthmatics still show poor disease control. We investigated the factors that may affect a reduced Omalizumab response in a large population of severe asthmatics. Methods: 340 patients were retrospectively evaluated. FEV1%, FVC%, Asthma Control Test (ACT), fractional exhaled nitric oxide (FENO), possible step-downs/step-ups of concomitant therapies, exacerbations, disease control levels, ICS doses and SABA use, observed at the end of treatment, were considered as a response to Omalizumab. Results: Age was an independent risk factor for a reduced response concerning FEV1%, FVC%, ACT and for a lower asthma control. O…

MaleSevere asthmaDrug ResistanceComorbidityOmalizumabOmalizumabAdrenal Cortex HormoneComorbidities0302 clinical medicineRetrospective StudieAdrenal Cortex HormonesRisk FactorsForced Expiratory VolumeAge FactorNasal polypsAnti-Asthmatic Agents030212 general & internal medicineMultivariate AnalysiSmokingAge FactorsReal-lifeMiddle AgedTreatment OutcomeItalyFemaleComorbiditieHumanmedicine.drugAdultage; comorbidities; obesity; omalizumab; real-life; severe asthma; therapeutic response; internal medicinemedicine.medical_specialtyLogistic ModelTherapeutic responseSettore MED/10 - Malattie Dell'Apparato RespiratorioNitric Oxide03 medical and health sciencesFEV1/FVC ratioNasal PolypsAgeInternal medicineInternal MedicinemedicineAnti-Asthmatic AgentHumansObesityRisk factorRetrospective StudiesAsthmabusiness.industryRisk Factormedicine.diseaseComorbidityAsthmarespiratory tract diseasesLogistic Models030228 respiratory systemConcomitantMultivariate AnalysisExhaled nitric oxideNasal PolypAge; Comorbidities; Obesity; Omalizumab; Real-life; Severe asthma; Therapeutic responsebusinessEuropean Journal of Internal Medicine
researchProduct

Effects of omalizumab in severe asthmatics across ages: A real life Italian experience

2016

Background This retrospective study aimed at evaluating long-term effects of Omalizumab in elderly asthmatics in a real-life setting. Methods 105 consecutive severe asthmatics (GINA step 4–5; mean FEV1% predicted:66 ± 15.7) treated with Omalizumab for at least 1 year (treatment mean duration 35.1 ± 21.7 months) were divided into 3 groups according to their age at Omalizumab treatment onset: 18–39, 40–64 and ≥ 65 years. Results Comorbidities, number of overweight/obese subjects and patients with late-onset asthma were more frequent among older people. A similar reduction of inhaled corticosteroids dosage and SABA on-demand therapy was observed in all groups during Omalizumab treatment; a sim…

MaleSevere asthmaPediatricsComorbidityOmalizumabOmalizumabOverweightImmunoglobulin ESeverity of Illness IndexElderly0302 clinical medicineAdrenal Cortex HormonesForced Expiratory VolumeAge effectAnti-Asthmatic Agentsasthma allergy elderly omalizumab030212 general & internal medicineYoung adultbiologyReal-lifeAdrenergic beta-AgonistsMiddle AgedTreatment OutcomeItalyFemalemedicine.symptommedicine.drugAdultPulmonary and Respiratory Medicineage effect; elderly; omalizumab; real-life; severe asthmamedicine.medical_specialtyAdolescentSettore MED/10 - Malattie Dell'Apparato RespiratorioAntibodies Monoclonal HumanizedYoung Adult03 medical and health sciencesAge effect; Elderly; Omalizumab; Real-life; Severe asthma; Pulmonary and Respiratory MedicineAdministration InhalationSeverity of illnessmedicineHumansAgedRetrospective StudiesAsthmabusiness.industryRetrospective cohort studyImmunoglobulin Easthmaallergymedicine.diseaseComorbidity030228 respiratory systembiology.proteinbusinessRespiratory Medicine
researchProduct

Hospital Care of Older Patients With COPD: Adherence to International Guidelines for Use of Inhaled Bronchodilators and Corticosteroids

2019

Abstract Objectives We aimed to analyze the prevalence and impact of COPD in older patients hospitalized in internal medicine or geriatric wards, and to investigate adherence to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, associated clinical factors, and outcomes. Design Data were obtained from REgistro POliterapie SIMI (REPOSI), a prospective multicenter observational registry that enrolls inpatients aged ≥65 years. Setting and Participants Older hospitalized patients enrolled from 2008 to 2016 with a diagnosis of COPD. Measures We evaluated adherence to the 2018 GOLD guidelines at admission and discharge, by examining the prescription of inhaled bronchodi…

Malemajor clinical eventmajor clinical eventsPulmonary Disease Chronic Obstructive0302 clinical medicineOlder patientsAdrenal Cortex Hormones80 and over030212 general & internal medicineLS4_4adherenceProspective StudiesGeneral NursingNursing (all)2901 Nursing (miscellaneous)Aged 80 and overCOPDHealth PolicyGeneral MedicineCOPD guidelines adherence major clinical events older patientsolder patientsObstructive lung diseaseBronchodilator Agentsguidelines adherenceHospitalizationInhalationCOPD; guidelines adherence; major clinical events; older patients; Administration Inhalation; Adrenal Cortex Hormones; Aged; Aged 80 and over; Bronchodilator Agents; Female; Humans; Male; Prospective Studies; Pulmonary Disease Chronic Obstructive; Guideline Adherence; HospitalizationAdministrationFemaleGuideline AdherenceCOPD guidelinesCOPD; guidelines adherence; major clinical events; older patients; Nursing (all)2901 Nursing (miscellaneous); Health Policy; Geriatrics and GerontologyChronic Obstructivemedicine.medical_specialtySocio-culturalePulmonary Disease03 medical and health sciencesolder patientInternal medicineAdministration InhalationmedicineHumansCOPDMedical prescriptionAgedPolypharmacybusiness.industrySettore MED/09 - MEDICINA INTERNAOdds ratiomedicine.diseaseConfidence intervalrespiratory tract diseasesCOPD; guidelines adherence; major clinical events; older patientsObservational studyGeriatrics and Gerontologybusiness030217 neurology & neurosurgery
researchProduct

Bone status assessed by quantitative ultrasound in children with inflammatory bowel disease: a comparison with DXA

2016

Background: To determine the bone status in children with inflammatory bowel diseases (IBD) using quantitative ultrasound (QUS) measurement at hand phalanges and compare the obtained results with dual-energy X-ray absorptiometry (DXA). Methods: Fifty-one children with IBD underwent DXA and QUS measurements at hand phalanges in the year 2013. The control group for the QUS consisted of 460 children. Reference data for DXA comes from Hologic Explorer. Results: QUS measurements did not differ significantly between IBD patients and healthy controls. There was no difference between UC and CD subjects. DXA measurements in patients with IBD were lower than in the healthy population. Tanner stage an…

Malemedicine.medical_specialtyAdolescentNutritional Status030209 endocrinology & metabolismInflammatory bowel diseasesInflammatory bowel diseaseFinger Phalanges03 medical and health sciencesquantitative ultrasoundAbsorptiometry Photon0302 clinical medicineCrohn DiseaseAdrenal Cortex HormonesBone DensityPredictive Value of TestsRisk FactorsInternal medicinemedicineHumansIn patientStage (cooking)Childbone mineral statusUltrasonographyBone mineralHepatologybusiness.industryHealthy populationAge FactorsGastroenterologyInflammatory Bowel DiseasesNutritional statusmedicine.diseasedigestive system diseasesQuantitative ultrasoundBone Diseases MetabolicNutrition AssessmentCase-Control StudiesColitis UlcerativeFemale030211 gastroenterology & hepatologyRadiologybusinessExpert Review of Gastroenterology & Hepatology
researchProduct

Regulation of argininosuccinate synthetase level by corticosteroid and pancreatic hormones during perinatal period.

1995

The urea cycle takes place in the hepatocyte of ureothelic animals. The conversion of ammonia into urea involves five reactions. The first 2 take place in the matrix of the mitochondria, the last 2 occur in the cytosol. Argininosuccinate synthetase (AS) is the third reaction of the urea cycle. It catalyses the condensation of citrulline and aspartate into arginonosuccinate. We have previously reported that rat AS activity was present in the cytosol and the outer membrane of the mitochondria. We have shown that, at the activity level, the colocation of AS was changing during fetal and neonatal development and was under the control of corticosteroid and pancreatic hormones. However, an unreso…

Malemedicine.medical_specialtyCytoplasmHydrocortisoneClinical BiochemistryArgininosuccinate synthaseMitochondria LiverMitochondrionArgininosuccinate SynthaseDexamethasoneDiabetes Mellitus Experimentalchemistry.chemical_compoundAdrenal Cortex HormonesPregnancyInternal medicinemedicineCitrullineAnimalsRats WistarMolecular BiologyPancreatic hormoneCells CulturedHypophysectomybiologyAdrenalectomyCell BiologyGeneral MedicineGlucagonPancreatic HormonesRatsCytosolmedicine.anatomical_structureEndocrinologychemistryAnimals NewbornLiverHepatocyteUrea cyclebiology.proteinFemaleHormoneMolecular and cellular biochemistry
researchProduct

Inflammatory bowel disease in patients over the age of 70y. Does the disease duration influence its behavior?

2018

Introduction: The fastest growing segment of our population is that of people above 70 years of age. Elderly patients with IBD exhibit several specific problems. Our objective was to evaluate the clinical course, the side effects of the treatments and the need for surgery of elderly patients, regardless of the age of onset.Materials and Methods: This was a cross-sectional study wherein retrospective data were collected from multiple centers from seven hospitals within the Valencia metropolitan area. Data were collected on patients older than 70y with inflammatory bowel disease.Results: We identified a total of 331 patients older than 70 years of age (5.3% of patients monitored at our center…

Malemedicine.medical_specialtyDisease durationPopulationComorbiditymacromolecular substancesInflammatory bowel diseaseGastroenterology03 medical and health sciencesElderly0302 clinical medicineAdrenal Cortex HormonesNeoplasmsInternal medicinemedicineHumansImmunologic FactorsIn patientMesalamineeducationAgedRetrospective Studiesulcerative colitisAged 80 and overCrohn's diseaseeducation.field_of_studybusiness.industrymusculoskeletal neural and ocular physiologyGastroenterologyInflammatory Bowel Diseasesmedicine.diseaseUlcerative colitisCrohn's diseaseCross-Sectional StudiesLogistic ModelsSpainSurgical Procedures Operative030220 oncology & carcinogenesisDisease ProgressionFemale030211 gastroenterology & hepatologybusiness
researchProduct

Cervical necrotizing fasciitis and descending necrotizing mediastinitis in a patient affected by neglected peritonsillar abscess: a case of medical n…

2007

Abstract We report a case of fatal cervical necrotizing fasciitis (CNF) and descending necrotizing mediastinitis (DNM) due to primary peritonsillar abscess in 60-year-old male patient with no history or evidence of immunocompromising disorders. The patient was treated with antibiotic and corticosteroid drugs but he developed mediastinitis and septic shock and died of multiple organ failure six days later from recovery in hospital. After a clinical, diagnostic and therapeutical consideration of the cervical necrotizing fasciitis and some related risks of a delayed diagnosis and treatment, the authors analysed the clinical history of the patient and of the medical conduct pointing out profess…

Malemedicine.medical_specialtyMultiple Organ FailureDelayed diagnosisPathology and Forensic MedicineFatal OutcomeSettore MED/43 - Medicina LegaleAdrenal Cortex HormonesMalpracticemedicineHumansFasciitis NecrotizingPeritonsillar AbscessFasciitisForensic PathologyLymphatic DiseasesPatient affectedbusiness.industrySeptic shockMalpracticeGeneral MedicinePeritonsillar AbscessMiddle Agedmedicine.diseaseMediastinitisPeritonsillar abscess cervical necrotizing fasciitis medical negligenceSurgeryAnti-Bacterial AgentsMediastinitisItalyMedical negligencebusinessLawJournal of forensic and legal medicine
researchProduct